Prescription medicine
Disopyramide Brand names: Norpace
Disopyramide (Norpace) is a prescription medicine with an FDA approval on record since 1977. FDA's NDC Directory lists it from 2 generic labelers, and pharmacies paid $0.801 per disopyramide 100 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
- Boxed warning
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the NDA 17447 record on Drugs@FDA; every disopyramide label on DailyMed.
Highlights of the record
FDA label of August 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of Norpace or Norpace CR as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.
Used for
From the label: indications and usageNorpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
Forms and strengths
- 100 mg
- 150 mg
Gelatin-coated capsule; capsule.
On the market
- Earliest approval on file
- September 1, 1977 Norpace, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 10 first February 22, 1985; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 2 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.801 per capsule Disopyramide 100 mg capsule
- Shortage (FDA)
- None current 2 past records
- Recalls by its makers (FDA)
- 3 since 2013 0 Class I among all firms' recalls; latest December 2, 2015
- FAERS reports
- 850 through July 30, 2026
What is disopyramide used for?
From the label: indications and usageNorpace and Norpace CR are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of Norpace and Norpace CR, their use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of Norpace or Norpace CR treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Norpace CR should not be used initially if rapid establishment of disopyramide plasma levels is desired. […]
FDA pharmacologic class: Antiarrhythmic.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
Is there a generic for disopyramide (Norpace)?
The FDA approved the first generic disopyramide on February 22, 1985. 10 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists disopyramide from 2 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1977 earliest approval on file
- 1985 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for disopyramide (Norpace)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.801 per Disopyramide 100 mg capsule, down 28% from $1.12 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Disopyramide 100 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Disopyramide 100 mg capsule | Generic | $0.801 per capsule | $24.02 | -28% |
| Disopyramide 150 mg capsule | Generic | $1.53 per capsule | $45.95 | -7% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is disopyramide in shortage?
No disopyramide presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 2 records are all marked to be discontinued, the latest updated August 24, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31) | Pfizer Inc. | To Be Discontinued | August 24, 2026 |
| Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31) | Pfizer Inc. | To Be Discontinued | August 24, 2026 |
Every disopyramide presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has disopyramide been recalled?
The FDA's Enforcement Report lists 3 recalls naming disopyramide since 2013: 0 Class I (the most serious), 1 Class II, 2 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 2, 2015 | Class III | Pfizer Inc. | Failed Dissolution Specification |
| July 2, 2013 | Class II | Aidapak Services, LLC | Labeling: Label Mixup: DISOPYRAMIDE PHOSPHATE, Capsule, 150 mg may have potentially been mislabeled as the following drug: THYROID, Tablet, 30 mg, NDC … |
| May 31, 2013 | Class III | Pfizer Inc | Failed Dissolution Specification |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the disopyramide label say about other medicines?
The disopyramide label names 13 other medicines in its interaction, contraindication or warning sections. The labels of 46 other medicines name disopyramide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clarithromycin | drug interactions | Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that coadministration of disopyramide with inhibitors of cytochrome 3A4 could result in potentially fatal interaction. |
| Diazepam | drug interactions | In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam. |
| Erythromycin | drug interactions | Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. |
| Flecainide | boxed warning | … excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). |
| Ketoconazole | drug interactions | Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. |
| Lidocaine | drug interactions | Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. |
| Phenytoin | drug interactions | Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. |
| Pilocarpine | warnings | … adequate overriding measures are taken; these consist of the topical application of potent miotics (e.g., pilocarpine) for patients with glaucoma, and catheter drainage or operative relief for patients with urinary retention. |
| Procainamide | drug interactions | Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. |
| Propafenone | warnings | Concomitant Antiarrhythmic Therapy The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who … |
| Propranolol | drug interactions | In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam. |
| Quinidine | drug interactions | Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. |
| Verapamil | drug interactions | Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration. |
Other labels that name disopyramide
- Anagrelide
- Artemether and lumefantrine
- Atenolol
- Betaxolol
- Bisoprolol
- Cobicistat
- Darunavir
- Etravirine
- Fosamprenavir
- Fosphenytoin
- Glimepiride
- Glipizide
- Glyburide
- Haloperidol
- Insulin aspart
- Insulin degludec
- Insulin detemir
- Insulin glargine
- Insulin glulisine
- Insulin human
- Insulin lispro
- Itraconazole
- Mavacamten
- Nebivolol
- Nevirapine
- Pramlintide
- Quinine
- Repaglinide
- Ritonavir
- Sotalol
- Toremifene
- Trazodone
- Vandetanib
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What do FAERS reports show for disopyramide?
The FDA Adverse Event Reporting System holds 850 reports that list disopyramide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 40 are coded as a death and 216 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other antiarrhythmics
- the pharmacologic class, with prices and generics
- Disopyramide side effects
- the label's list beside FAERS reports
- Disopyramide shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other